The FINANCIAL — Bayer Schering Pharma AG, Germany, and Bayer Yakuhin, Ltd., Japan, announced that the Japanese regulatory authorities have granted approval for YAZ (3 mg drospirenone/20 mcg ethinyl estradiol) for the treatment of dysmenorrhea.
"There are 27 million women of reproductive age in Japan, and one third of them are recognized to have menstrual pain, which can be related to dysmenorrhea and requires some form of medical intervention. The introduction of this new treatment will contribute to improving women´s quality of life and offer a new option to respond to unmet medical needs," Bayer informs.
YAZ is available in the US, Europe, Latin America and the region Asia Pacific. In the US and several other countries in various regions, it is approved as an oral contraceptive as well as for the treatment of the symptoms of Premenstrual Dysphoric Disorder (PMDD) and/or moderate acne vulgaris in women desiring oral contraception.